Previous 10 | Next 10 |
From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years including 98 weeks of public weekly selections as part of this ongoing live forward-testing. In 2017, the sample size began with 12 stocks, then 8 stocks in...
On Thursday, March 7, AcelRx (NASDAQ: ACRX ) reported its 2018 financial results , presenting a strong picture overall. With a large cash balance and controlled burn rate, AcelRx is in an excellent position to build a market share for Dsuvia and demonstrate the sustainability of the company'...
The following slide deck was published by AcelRx Pharmaceuticals, Inc. in conjunction with this Read more ...
REDWOOD CITY, Calif. , March 11, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management...
Call Start: 16:30 Call End: 17:19 AcelRx Pharmaceuticals, Inc. (ACRX) Q4 2018 Earnings Conference Call March 7, 2019, 4:30 pm ET Company Participants Raffi Asadorian - CFO Vince Angotti - CEO Pam Palmer - CMO Conference Call Participants Ashley Ryu - RBC Brandon Folke...
AcelRx Pharmaceuticals (NASDAQ: ACRX ): Q4 GAAP EPS of -$0.18 beats by $0.02 . Revenue of $0.61M (-17.6% Y/Y) misses by $0.89M . Shares -4.3% . Press Release More news on: AcelRx Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
REDWOOD CITY, Calif. , March 7, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today provided a business update and reported its fourth quarter an...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on winning breakout selections over more than 5 years including 94 weeks of public weekly selections as part of this ongoing live forward-testing. Breakout Stock Portfolio 2019 results YTD All time total...
AcelRx Still Gets Little Valuation For Dsuvia AcelRx is ready to launch Dsuvia, its proprietary sublingual formulation of sufentanil. Dsuvia was developed to be a safer, faster-acting opioid alternative to intravenous morphine for acute pain in hospital settings. It relives pain faster t...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...